Local anesthetic combination with NSAID and vasopressor

This page covers all Local anesthetic combination with NSAID and vasopressor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline), Voltage-gated sodium channels (chirocaine); COX-1/COX-2 (ketorolac); alpha-1 and beta-adrenergic receptors (epinephrine).

Targets

Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline) · Voltage-gated sodium channels (chirocaine); COX-1/COX-2 (ketorolac); alpha-1 and beta-adrenergic receptors (epinephrine)

Marketed (1)

• Ropivacaine, Ketorolac and Adrenaline · University of Aarhus · Anesthesia and Pain Management
  This combination provides local anesthesia via sodium channel blockade (ropivacaine), pain relief through COX inhibition (ketorolac), and vasoconstriction with sympathomimetic effects (adrenaline).

Phase 3 pipeline (1)

• Chirocaine ketorolac epinephrine · maximiliano barahona vasquez · Pain Management, Surgery, Anesthesia
  This combination drug provides local anesthesia via chirocaine, reduces inflammation and pain via ketorolac, and enhances vasoconstriction and hemostasis via epinephrine.